GCP (Good Clinical Practice), Clinical Research and Inspection Training Course: Regulatory Compliance, Recent Legislation, and Technological Advances (ONLINE EVENT: July 7, 2025)
Dublin, May 28, 2025 (GLOBE NEWSWIRE) -- The "GCP (Good Clinical Practice) and Clinical Research Update - Hot Inspection Topics Training Course" training has been added to ResearchAndMarkets.com's offering.
Clinical research is a constantly evolving field and the regulatory requirements are frequently being updated. In order to stay ahead and maintain your GCP knowledge, it is important to receive regular training.
This must-attend course provides a review of recent changes to relevant guidance and legislation and will look at how these developments have been implemented and are likely to be implemented. Topics covered will include the EU Clinical Trials Regulation and associated documents and an update on ICH GCP R3
This is a highly interactive course suitable for those who need to refresh their knowledge and to demonstrate recent and up-to-date training to regulatory inspectors.
Who Should Attend:
The course is of particular relevance for those working in clinical research, regulatory affairs and pharmacovigilance, QA, Audit, CROs, academic trialists and regulatory inspectors. It will also be of interest to those departments who liaise/support clinical trial personnel and all other professionals who want to know more about updates in GCP regulations and guidelines covering clinical trials.
Benefits of attending
Be updated on ICH GCP R3
Discuss recent developments in GCP and clinical trial legislation and guidance in the EU, FDA considerations
Review the requirements of clinical trail essential documentation
Identify common audit and inspection findings to help prepare for inspection
Understand the EU Clinical Trial Regulation requirements
Clarify requirements for data integrity and governance
Explore technology advances in clinical trials
Certifications:
CPD: 6 hours for your records
Certificate of completion
Key Topics Covered:
Brief review of regulatory authority inspection findings
EMA, MHRA and FDA findings
New ICH GCP E6 R3 draft guideline
What is new and likely to impact on running trials
Revised principles
Data governance
Records and reports
Key updates, additions and revisions
ICH E8
Other ICH updates
European Commission Guidelines on Good Clinical Practice specific to Advanced Therapy Medicinal Products (ATMPs)
ICH E8
Data integrity governance
What inspectors look for
MHRA integrity guidance compliance
ICH GCP R3 Governance requirements
EU Clinical Trial Regulation (536/2014) update
Key changes and documentation
Update since go-live
Clinical Trials Information System (CTIS)
EU clinical trial authorisation
Serious Breaches
Essential records: EMA key requirements to avoid inspection findings, and documents requirement in ICH GCP E6 R3
TMF structure, content, security, control, maintaining the TMF and storage, e-TMFs, archiving and retention
ICH GCP R3 - recommended format for compliance
Awareness update from EU and FDA
EU
EMA Guidance on validation & qualification of computerised systems
European Commission Guidelines on Good Clinical Practice specific to Advanced Therapy Medicinal Products (ATMPs)
Artificial intelligence reflection guidance in lifecycle
Stronger enforcement of the GDPR in cross-border cases
Real-world data
FDA
Guidance for industry: considerations for the use of real-world data
FDA guidance on enhancing the diversity of clinical trials
A risk-based approach to monitoring of clinical investigations
Informed consent guidance for IRBs, clinical investigators and sponsors
Digitalisation and technology advances and GCP
Technology innovations in clinical research
Electronic informed consent
Apps, medical devices and mobile technologies in clinical trials
Artificial intelligence
Decentralised clinical trials
Conclusion and final Q&A
Speakers: Laura Brown Pharmaceutical QA and Training Consultant University of Cardiff Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. She has more than 20 years' experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International.
She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry. She regularly writes on pharmaceutical regulatory issues including "The Planning of International Drug Development", in the Clinical Research Manual, Euromed and the "Impact of Brexit", RQA Journal 2017. For more information about this training visit https://www.researchandmarkets.com/r/5y28mn
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
China's Biotech Is Quietly Eating Big Pharma's Lunch
Chinese biotech is no longer playing catch-up it's becoming the main event. In 2024, more than 1,250 innovative drugs entered development in China, nearly overtaking the US and leaving the EU behind. This isn't just a numbers game. Chinese firms like Akeso (AKESF) are now developing therapies that are outperforming global blockbusters like Merck's Keytruda in head-to-head trials. The quality leap has been fast, fueled by regulatory reforms, foreign-trained scientists, and an R&D machine that moves at blistering speed. Data from Norstella shows China now earns more expedited drug reviews than the EU a signal that Western regulators are paying attention. Warning! GuruFocus has detected 7 Warning Signs with AKESF. Multinational pharma isn't waiting around. Pfizer (NYSE:PFE) just cut a $1.2 billion upfront deal with 3SBio. Summit Therapeutics paid $500 million for rights to Akeso's cancer therapy. These aren't niche plays they're big bets on the future. And with China's massive patient pool and streamlined hospital network, companies can run trials in half the time (and at a fraction of the cost) compared to the US. That speed lets Chinese firms launch multiple shots on goal and global players are lining up to license the winners. From cell therapies to obesity drugs, the East is becoming the place where the drug pipeline gets built. But approval is still a long game. US regulators aren't greenlighting drugs based solely on China trial data not yet. And with rising geopolitical tension, some in Washington are sounding alarms over biotech dependencies. Still, the shift is underway. In just five years, the number of top-ranked Chinese drug innovators has quadrupled. Investors watching this space aren't asking whether China will lead the next wave of biotech innovation. They're asking how soon. This article first appeared on GuruFocus.
Yahoo
27 minutes ago
- Yahoo
Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J., July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing. Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. The test is the first blood-based IVD test cleared by the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. It is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. Through its AD-Detect™ portfolio, Quest provides a suite of advanced lab-developed blood tests regulated under CLIA for assessing patients with cognitive impairment for Alzheimer's disease. The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings. "Our goal is to advance access to quality and innovative blood-based tests for Alzheimer's disease. Adding the Fujirebio test to our existing blood-based tests provides the many physicians we serve with another powerful option for assessing patients for Alzheimer's disease," said Kathleen Valentine, Vice President and General Manager, Neurology, Quest Diagnostics. "Blood-based testing can be less invasive and more convenient than traditional test methods. We are excited to leverage our expansive network of patient service centers to broaden access to the Fujirebio innovation to help more at-risk individuals gain access to the insights they need sooner." In a clinical study population of 499 patients, which closely mirrors US demographics, and when applying a dual cut point, the FDA-cleared test demonstrated a positive predictive value (PPV) of 92% and a negative predictive value (NPV) of 97%, with 20% of patients uncertain to have amyloid pathology, thus requiring further testing. Quest will showcase its complete line up of Alzheimer's and other neurological test innovations at this year's Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31. "As brain health and Alzheimer's disease interventions continue to evolve, diagnosing patients earlier, when interventions can be most effective, is critical," said Michael Racke, MD, a board-certified neurologist and Medical Director of Neurology, Quest Diagnostics. "We are constantly looking for ways to help physicians and patients make the most informed decisions, and this new addition to our test menu will aid that goal." While amyloid PET imaging and cerebral spinal fluid testing are established methods for aiding the diagnosis of Alzheimer's disease, they are significantly more expensive, invasive and specialist-dependent than blood-based tests. With a physician's order, patients can conveniently provide a blood draw for testing for the Fujirebio test and any of the AD-Detect™ tests through Quest's network of patient sites. Quest maintains approximately 8,000 patient access points, including an extensive patient service center network of approximately 2,000 locations in the U.S., as well as phlebotomists in physician offices and mobile phlebotomy services. Specimens will be transported for testing to Quest's state-of-the-art laboratory in San Juan Capistrano, California. Nearly 7 million Americans have Alzheimer's, the most prevalent dementia, a number projected to reach 14 million by 2060. Approximately 12-18% of adults over the age of sixty are living with mild cognitive impairment, a potential sign of AD. Seventy-seven percent of physicians say new therapies will transform Alzheimer's into a chronic, manageable disease, and 94% of physicians say blood tests would be more cost effective for the healthcare system compared to more invasive methods of detection (e.g., lumbar puncture, imaging studies) according to a special report from Quest. Quest is committed to developing and offering innovative advanced diagnostics to aid in evaluating Alzheimer's disease and other brain diseases. For more information, visit About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. View original content to download multimedia: SOURCE Quest Diagnostics
Yahoo
31 minutes ago
- Yahoo
Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board
MADISON, Wis., July 14, 2025--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies. Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a clinical stage biotech company in Pittsburgh, PA. Most recently, he served as Senior Vice President of Human Immunology at Vir Biotechnology. Prior to that, he served as Vice President for Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS), where he led the development of biologics for tumor immunotherapy. During his tenure at BMS and Medarex, Dr. Korman contributed to the development of three approved oncology drugs: ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), and relatlimab (anti-LAG-3), as well as their combination, pioneering the use of immune checkpoint blockade in cancer therapy. Dr. Korman earned his PhD in Cellular and Developmental Biology from Harvard University and was a Whitehead Fellow at the Whitehead Institute at the Massachusetts Institute of Technology. He also served as a staff scientist at the Institut Pasteur before transitioning to the biotechnology sector. In addition to his new role on Invenra's SAB, Dr. Korman is also the founder of Spice Biotechnologies, a company focused on developing next-generation checkpoint therapeutics. "We are thrilled to welcome Dr. Korman to our Scientific Advisory Board," said Dr. Roland Green, Co-Founder, CEO, and Chairman of Invenra. "His extensive experience in developing transformative immunotherapies aligns perfectly with Invenra's mission to collaborate with and support biotech and pharmaceutical companies of all sizes globally. We look forward to his valuable insights and contributions as we continue to empower our partners to advance innovative therapeutics." Dr. Korman joins SAB members Dr. Paul Sondel and Dr. Jonathan Davis, whose knowledge and guidance have supported Invenra's research and development. Dr. Paul Sondel, MD, PhD, is the Reed and Carolee Walker Professor in Pediatric Oncology at the University of Wisconsin–Madison. With a distinguished career in cancer immunotherapy, Dr. Sondel has led lab, translational, and clinical research within the UW Carbone Cancer Center. His work has significantly advanced the understanding and application of immunotherapeutic strategies, including the development of FDA-approved treatments for high-risk neuroblastoma. Dr. Jonathan Davis, PhD, brings over 20 years of experience in the life sciences industry, focusing on protein and antibody engineering, as well as bispecific and multispecific antibody platform development. Prior to joining the Invenra SAB, Dr. Davis was Vice President of Innovation and Strategy for Invenra where he focused on optimization of the B-Body Platform, the development of antibody libraries, and refinements to screening methodology and throughput. Prior to Invenra, he was a Principal Scientist at Bristol-Myers Squibb, where he contributed to biologic drug design, including the development of a trispecific HIV biotherapeutic. Prior to that, he worked at EMD Serono, where he developed a variety of novel biologic drug platforms. "The collective expertise of Drs. Korman, Sondel, and Davis positions Invenra as a key collaborator and service provider, driving the discovery and development of multispecific antibody-based therapeutics in partnership with biotech and pharmaceutical companies worldwide," added Dr. Green. "Their combined knowledge and experience will be invaluable as we continue to support our partners in bringing novel treatments to patients in need." For more information about Invenra and its Scientific Advisory Board, please visit About Invenra Invenra Inc. is a biotechnology company specializing in next-generation multispecific antibody discovery and development. Its proprietary B-Body® platform enables the rapid generation of highly developable bispecifics and now supports both Rapid Bispecific Discovery Services—delivering lead panels in as little as four months—and B-Body Express™, which quickly produces high-quality bispecifics from partner-provided sequences. Invenra's newly launched T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development. View source version on Contacts Invenra Inc.5510 Element Way, Suite 400Madison, WI 53719Phone: 608.441.8319Email: info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
